GLENMARK — Glenmark Pharmaceuticals Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedLarge CapHigh Flyer

Annual income statement for Glenmark Pharmaceuticals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2020 March 31st	2021 March 31st	2022 March 31st	R2023 March 31st	2024 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	Interim Report	PRESS
Standards:	IAS	IAS	IAS	—	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	106,410	109,439	123,049	115,832	118,131
Cost of Revenue
Gross Profit	64,322	66,167	73,261	73,257	73,997
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	93,260	92,586	107,258	112,833	121,006
Operating Profit	13,150	16,854	15,791	3,000	-2,875
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	10,961	13,825	14,412	2,398	365
Provision for Income Taxes
Net Income After Taxes	7,760	9,701	9,936	-896	-18,309
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	7,760	9,701	9,417	2,972	-15,017
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	7,760	9,701	9,417	2,972	-15,017
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	26.7	33.3	39.9	11.6	-46.5
Dividends per Share